Ribo Life Science Files for Hong Kong IPO: A Leading Chinese siRNA Therapeutics Company Poised to Enter Capital Markets

According to the Zhicheng Finance APP, on April 25, Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to as "Ribo Life Science" or "the Company") officially submitted the A1 listing application form to the Hong Kong Stock Exchange. Established in 2007, Ribo Life Science focuses on the development of RNA interference (RNAi) technology and the industrialization of small nucleic acid drugs, being one of the earliest pioneers in this field globally. Throughout its development history, the company has received strategic investments from several well-known institutions such as Legend Capital, SDIC Innovation, China Venture Capital, and Panlin Capital.

Focus on Breakthrough siRNA Therapies, LeadingChinaThe Wave of Small Nucleic Acid Drug Development

Following small molecule and antibody drugs, small nucleic acid drugs, as a completely new therapeutic paradigm, are forming the third wave of modern pharmaceuticals. Globally, more than 20 small nucleic acid drugs have been approved for marketing. According to Frost & Sullivan data, the global small nucleic acid drug market grew from $2.7 billion in 2019 to $4.6 billion in 2023, with a compound annual growth rate (CAGR) of 14.3%. Driven by continuous technological advancements, increasing regulatory approvals, and growing clinical validation, the global small nucleic acid drug market is expected to accelerate its growth, reaching $46.7 billion by 2033.

Among them, small interfering RNA (siRNA) drugs represent the most disruptive direction in nucleic acid pharmaceuticals, with the potential to break through the traditional "high-risk" model of innovative drug R&D. On one hand, siRNA technology can increase the success rate of clinical development from less than 10% for traditional drugs to over 60%. On the other hand, it can significantly shorten the R&D cycle, requiring only 20-24 months from target identification to clinical application. Additionally, for many patients with chronic diseases, the ultra-long-acting mechanism of siRNA drugs allows a single administration to maintain efficacy for 6-12 months, greatly enhancing treatment effectiveness and patient compliance.

Internationally, companies mainly engaged in the layout of siRNA therapy include Alnylam, Arrowhead, Novartis, and Novo Nordisk. Ribo Life Science, which has recently filed for listing on the Hong Kong Stock Exchange, is the small nucleic acid pharmaceutical company with the most clinical-stage assets in China. Through independent innovation, it has established a rich pipeline of siRNA drugs, covering multiple disease areas, especially chronic disease treatment fields such as cardiovascular, metabolic, renal, and liver diseases.

Currently, there remains a significant unmet demand in the chronic disease treatment market. Long-acting therapeutic solutions represented by small nucleic acid drugs are regarded as a new breakthrough in the chronic disease field. In 2021, Novartis' siRNA drug Inclisiran, which targets the PCSK9 protein, was approved by the FDA for treating hypercholesterolemia. Requiring only two subcutaneous administrations per year, it has revealed the enormous potential of small nucleic acid drugs in the field of chronic disease treatment. At present, multiple small nucleic acid drugs are being developed globally for the treatment of chronic diseases such as hyperlipidemia, hypertension, and hyperglycemia, marking the beginning of a new era in the race to develop chronic disease treatments.

According to the prospectus, Ribo Life Science currently has six self-developed siRNA drugs in clinical trials, covering seven indications, four of which have entered Phase 2 clinical trials; there are also more than 20 preclinical assets being actively advanced. The company’s core product in cardiovascular, metabolic, and renal diseases, RBD4059, is the first in its category globally to advance to clinical trials and is progressing the fastest (First-In-Modality). The key product RBD5044 has Best-In-Class potential; the pivotal product RBD1016 will serve as a cornerstone therapy in combination treatments for hepatitis B virus in the field of liver diseases and is key to achieving functional cures. Other pipelines under development also include several products with globally leading FIC or BIC potential.

(Screenshot of the Prospectus Pipeline)

Ribo Life Science's core product RBD4059 is the world’s first siRNA drug for the treatment of thrombotic diseases and is currently the most advanced in clinical development, now in Phase 2 clinical trials. RBD4059 achieves its anticoagulant/antithrombotic effect by inhibiting FXI and blocking the activation of the intrinsic coagulation pathway. It not only has the potential to become a more effective antithrombotic treatment but also offers the advantage of minimal bleeding risk. Its long-lasting effect allows for low-frequency dosing, which can improve patient compliance, making it an optimal treatment choice for a wide range of patients with thrombotic diseases.

Thrombotic diseases have become one of the leading causes of death globally, with one in four deaths associated with thrombotic diseases. According to Frost & Sullivan data, there were approximately 38.3 million patients with thrombotic diseases worldwide in 2023, and this number is expected to increase to 41.4 million by 2033. Currently, there are no FXI-targeted drugs approved globally for the treatment of thrombotic diseases. In October 2024, RBD4059 completed a Phase 1 clinical trial involving healthy subjects in Australia, and in August of the same year, it received approval from the European Medicines Agency (EMA) to initiate a Phase 2a clinical trial. In February 2025, patient enrollment for the Phase 2a trial was completed, and the trial is expected to be completed by the end of 2025.

In the field of hyperlipidemia, Ribo Life Science's key investigational product RBD5044 is the world's second siRNA drug targeting APOC3 to enter clinical development, showing the best potential (Best-In-Class) among siRNA candidates for treating hypertriglyceridemia. According to data from Frost & Sullivan, globally, the prevalence of adult dyslipidemia is estimated at approximately 40%, affecting about 3 billion people annually, with hypertriglyceridemia accounting for roughly 25% of all cases. In 2023, around 800 million people worldwide were affected by hypertriglyceridemia, a number expected to reach 900 million by 2033. However, existing treatments for hypertriglyceridemia have certain limitations, such as risks of hepatotoxicity, myopathy, gastrointestinal disorders, and pancreatitis. As of December 31, 2024, there are no approved APOC3-targeted therapies globally for treating hypertriglyceridemia. With the low-frequency dosing and long-lasting efficacy characteristics of siRNA therapy, RBD5044 is expected to provide patients with a more convenient treatment option compared to the daily medication paradigm.

In addition, Ribo Life Science's RBD7022 is the second globally to enter clinical development and is also a promising PCSK9-targeted siRNA for treating hypercholesterolemia. To date, Inclisiran is the only globally approved PCSK9-targeted siRNA drug for treating hypercholesterolemia, with global sales reaching $754 million in 2024, marking a year-over-year increase of 112%. The preclinical and Phase 1 clinical trial results of Ribo Life Science's RBD7022 have demonstrated LDL-C lowering effects comparable to Inclisiran, highlighting its potency and long-lasting efficacy. It also has the potential for dosing every six months, making it a strong contender in this field. Additionally, in December 2023, the company granted Qilu Pharmaceutical Co., Ltd. ("Qilu Pharma") exclusive rights for the development, manufacturing, and commercialization of RBD7022 in mainland China, Hong Kong, and Macao, in a deal worth a total of RMB 700 million.

Another key investigational product of the company, RBD1016, is an siRNA candidate drug for the treatment of chronic hepatitis B, and represents a crucial pillar therapy in the future combination approach to achieve functional cure of hepatitis B. The Phase 1 clinical trial results of RBD1016 have already demonstrated a sustained reduction in HBsAg following a single dose, showing good safety and tolerability. The Phase 2a clinical trial of RBD1016 was fully enrolled with all patients by November 2024. To date, no siRNA drugs have been approved globally for the treatment of chronic hepatitis B.

It is worth mentioning that the aforementioned key pipeline products of Ribo Life Science were all developed through the company's self-developed RiboGalSTAR™ liver-targeting delivery platform, representing the cutting-edge of global innovation and demonstrating good safety, potent efficacy, and long-lasting effects in clinical studies to date.

Ribo Life Science, as one of the earliest companies in China to focus on the development of small nucleic acid drugs, has established a strong global intellectual property portfolio. As of December 31, 2024, Ribo Life Science owns 458 patents in major jurisdictions such as China, the European Union, the United States, and Japan, including 229 approved patents and 229 pending applications. These patents cover small nucleic acid sequences, chemical modifications, targeted delivery technologies, combination therapies, and clinical applications, making it one of the small nucleic acid pharmaceutical companies with the largest number of patents globally.

Global R&D Strategy and Management Team Drive Dual Progress; Self-Developed Technology Platform Recognized by Multinational Pharmaceutical Companies

Ribo Life Science, with its global strategic layout, has established a mature clinical professional team and clinical trial base in Europe, realizing the transformation and upgrading from a "biotechnology company" to an "international pharmaceutical company," successfully placing itself at the forefront of the global small nucleic acid pharmaceuticals industry.

In the fierce global biopharmaceutical competitive landscape, the development code of Ribo Life Science lies in its "dual-driven" approach of global R&D strategy and international management team. The company's management team, which possesses a deep international perspective and top-level industry expertise, is composed of members with decades of multinational pharmaceutical experience, injecting strong strategic decision-making and execution capabilities into the enterprise.

In the construction of its R&D system, Ribo Life Science has established a global R&D network. The team, composed of nearly 300 R&D personnel, is led by several international experts who have previously served as executives in global multinational corporations. In China, the Beijing R&D center relies on its self-developed core technology platforms and advanced experimental equipment, focusing on drug discovery and preclinical research while continuously exploring innovative targets. The Suzhou R&D center, on the other hand, concentrates on medicinal chemistry and CMC development and production, providing robust and comprehensive support for drugs transitioning from the laboratory to clinical trials. Ribo Life Science is also one of the few small nucleic acid drug development companies globally with full independent CMC capabilities. It not only possesses an advanced integrated system for process development, chemical analysis, technology transfer, and regulatory submissions but also has production lines that meet EU GMP standards and have obtained QP certification, supporting the company through all stages of drug development from early research to Phase 3 clinical trials.

In its global expansion, the Swedish R&D center Ribocure AB serves as a "strategic fulcrum," deeply integrating research facilities with the specialized clinical trial unit (CTU), Ribocure Clinic. Strictly adhering to international regulatory and ICH standards, it has independently initiated two Phase 2 clinical trials, with an expected enrollment of over 100 patients, significantly enhancing the efficiency and quality of clinical research. Additionally, the Scientific Advisory Board, composed of seven world-class scientists with extensive expertise in therapeutic fields and small nucleic acid drug development, provides precise strategic guidance for the siRNA pipeline R&D.

With the support of a robust R&D system and team, the company has established an independent and controllable small nucleic acid drug R&D platform that integrates the entire technology chain, supporting the full life cycle of small nucleic acid drugs from early R&D to industrialization. The self-developed GalNAc small nucleic acid drug delivery technology platform, RiboGalSTARTM, features highly specific liver targeting, high potency, and long-lasting effects, reaching an internationally competitive level.

RiboGalSTAR™ Liver-Targeted Delivery Platform is the world's first innovative delivery technology developed and licensed out by a Chinese company. RiboGalSTAR™ has advanced six products into clinical studies in the fields of cardiovascular, metabolic, renal, and liver diseases. Additionally, Ribo Life Science has made breakthrough progress in extrahepatic delivery technology. RiboOncoSTAR™ is a globally leading tumor-targeting technology platform that supports the company in developing multiple potential first-in-class cancer therapies. The RiboPepSTAR™ technology platform, targeting other extrahepatic tissues, has demonstrated significantly superior efficacy compared to existing treatments in multiple disease models for kidney and central nervous system delivery, with excellent safety.

Relying on an advanced technology platform, Ribo Life Science has reached the only technology platform-based collaboration in the RNAi field between a Chinese biotech company and a global multinational corporation to date, with Boehringer Ingelheim of Germany. The deal is worth over 20 billion US dollars in total. The method of licensing cooperation for the technology platform is more significant than that for individual products, representing the high recognition by multinational pharmaceutical companies of Ribo Life Science's R&D platform and scientific research strength. In January 2025, Ribo Life Science announced the achievement of the first milestone in its collaborative research with Boehringer Ingelheim. Within less than a year from the project’s initiation, Ribo Life Science once again demonstrated to the world the solidity of the company's small nucleic acid technology platform as well as the team's outstanding and highly efficient international cooperation capabilities.

From technological breakthroughs to global pipeline layouts, from independent research and development to international collaborations, Ribo Life Science has been deeply committed to the small nucleic acid drug field for 18 years. Currently, the company has built a unique competitive barrier in the global small nucleic acid pharmaceutical race and is accelerating its progress toward becoming a leading global biopharmaceutical enterprise. In the future, Ribo Life Science will continue to set sail with innovation and steer with globalization, accelerating into the deep sea of the biopharmaceutical industry. It aims to bring more groundbreaking treatment options to patients worldwide, fill gaps in clinical therapies, write a new chapter in China's small nucleic acid drug research and development, and push China’s RNAi technology to the forefront of the world.